2. Search Result
Search Result
Results for "

anti-HBV

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Peptides

3

Inhibitory Antibodies

16

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0056
    Isochlorogenic acid A
    5+ Cited Publications

    3,5-Dicaffeoylquinic acid; 3,5-CQA

    		 Reactive Oxygen Species HBV Endogenous Metabolite HIV Bacterial Neurological Disease Inflammation/Immunology
    Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is a natural phenolic acid with anti-mutagenicity, anti-HBV, anti-HIV, anti-oxidant, anti-bacterial, and anti-inflammatoryy activities .
    Isochlorogenic acid A
  • HY-149392
    HBV-IN-35

    		HBV Infection
    HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC50: 100 nM and 400 nM respectively) .
    HBV-IN-35
  • HY-148782
    HBV-IN-31

    		HBV Infection
    HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC50 value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .
    HBV-IN-31
  • HY-148783
    HBV-IN-32

    		HBV Infection
    HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC50 value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth .
    HBV-IN-32
  • HY-N8168
    LPRP-Et-97543

    		HBV Infection
    LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research .
    LPRP-Et-97543
  • HY-N10404
    Junceellolide C

    		HBV Inflammation/Immunology
    Junceellolide C is a transcription inhibitor of cccDNA. Junceellolide C inhibits HBV DNA replication and significantly decreases the level of supernatant HBV RNA with EC50 values of 5.19, 3.52 μM respectively in HepAD38 cells. Junceellolide C is a potent anti-HBV agent .
    Junceellolide C
  • HY-N8153
    Glycosmisic acid

    		HBV Infection Inflammation/Immunology
    Glycosmisic acid, a natural compound, possesses anti-HBV activity .
    Glycosmisic acid
  • HY-131343
    HBV-IN-4

    		HBV DNA/RNA Synthesis Infection
    HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies .
    HBV-IN-4
  • HY-N2988
    Schisanwilsonin C

    Arisanschinin K

    		 HBV Infection Inflammation/Immunology
    Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity .
    Schisanwilsonin C
  • HY-145059
    HBV-IN-12

    		HBV Infection
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15 .
    HBV-IN-12
  • HY-148784
    Neracorvir

    		HBV Infection
    Neracorvir is a potent antiviral agent. Neracorvir exhibits anti-HBV activity .
    Neracorvir
  • HY-P99608
    Exbivirumab

    		HBV Infection
    Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
    Exbivirumab
  • HY-P3601
    Brain Derived Basic Fibroblast Growth Factor (1-24)

    FGF basic (1-24)

    		 Bacterial HBV Infection Inflammation/Immunology
    Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research .
    Brain Derived Basic Fibroblast Growth Factor (1-24)
  • HY-W018791
    Bifendate

    DDB

    		 HBV Infection
    Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-HBV efficacy in research of chronic hepatitis B .
    Bifendate
  • HY-107026
    Lagociclovir valactate

    		HBV Infection
    Lagociclovir valactate is a prodrug of Lagociclovir (HY-14844). Lagociclovir valactate is an orally active anti-HBV agent .
    Lagociclovir valactate
  • HY-N1323
    Sanggenol P

    		HBV Infection
    Sanggenol P, a flavonoid, shows anti-HBV activity on HepG2.2.15 cell line in vitro .
    Sanggenol P
  • HY-139574
    Firzacorvir

    		HBV Infection Inflammation/Immunology
    Firzacorvir is a cyclic sulfamide compound and modulates HBV core protein. Firzacorvir has anti-HBV activity with EC50 < 1 μΜ .
    Firzacorvir
  • HY-N2192
    Swertianolin

    Swertianolin, a xanthone isolated from Gentianella Acuta, inhibits acetylcholinesterase (AChE). Swertianolin also exhibits anti-HBV and anti-bacterial activity .
    Swertianolin
  • HY-123336
    Schisantherin C

    		HBV Infection
    Schisantherin C exhibits anti-HBV activity with potency against HBsAg and HBeAg secretion by 59.7% and 34.7% at 50μg/mL .
    Schisantherin C
  • HY-111003
    Isothiafludine

    NZ-4

    		 HBV Infection
    Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation .
    Isothiafludine
  • HY-124600
    NVR 3-778
    1 Publications Verification

    		 HBV Infection
    NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity .
    NVR 3-778
  • HY-151134
    HBV-IN-25

    		HBV Infection
    HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA＞452 μg/mL) and good PK property with no cellular toxicity .
    HBV-IN-25
  • HY-149435
    HBV-IN-36

    		HBV Infection
    HBV-IN-36 (compound 42) is a HBV inhibior (IC50=2 μM), showing anti-HBV activity with EC50 of 0.58 μM .
    HBV-IN-36
  • HY-P990015
    Tobevibart

    		HBV Infection
    Tobevibart is an IgG1-lambda, anti-HBV (hepatitis B virus) surface envelope protein human monoclonal antibody. Tobevibart shows antiviral activity .
    Tobevibart
  • HY-16679
    Helioxanthin derivative 5-4-2
    1 Publications Verification

    Helioxanthin 5-4-2

    		 HBV Infection
    Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.
    Helioxanthin derivative 5-4-2
  • HY-P99703
    Libivirumab

    17.1.41

    		 HBV Infection
    Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
    Libivirumab
  • HY-N0820
    Catalpol
    5+ Cited Publications

    Catalpinoside

    		 HBV Infection Neurological Disease Inflammation/Immunology Cancer
    Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
    Catalpol
  • HY-109197
    Vonafexor
    1 Publications Verification

    EYP001

    		 FXR HBV Infection
    Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .
    Vonafexor
  • HY-155547
    HBV-IN-34

    		HBV Infection
    HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC50 of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively .
    HBV-IN-34
  • HY-126033
    Sophoranol

    		HBV RSV Infection
    Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL .
    Sophoranol
  • HY-B1464
    Cetylpyridinium chloride
    2 Publications Verification
    Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-HBV capsid assembly inhibitor with an IC50 of 2.5 μM. Cetylpyridinium chloride is used in pesticides and various types of mouthwashes, and other personal care products .
    Cetylpyridinium chloride
  • HY-149357
    Yhhu6669

    		HBV Infection
    Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties .
    Yhhu6669
  • HY-13859
    Clevudine

    L-FMAU

    		 HBV DNA/RNA Synthesis Orthopoxvirus Infection
    Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
    Clevudine
  • HY-116999
    IR415

    		HBV Infection
    IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (Kd=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease . HBx: hepatitis B virus X protein.
    IR415
  • HY-B0150
    Nicotinamide
    Maximum Cited Publications
    36 Publications Verification

    Niacinamide; Nicotinic acid amide

    		 Organoid Endogenous Metabolite Sirtuin HBV Cancer
    Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide
  • HY-B0150A
    Nicotinamide Hydrochloride

    Niacinamide Hydrochloride; Nicotinic acid amide Hydrochloride
    Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD+, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity .
    Nicotinamide Hydrochloride
  • HY-100028
    AT-130
    1 Publications Verification
    AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells .
    AT-130
  • HY-N11792
    Pedunculosumoside F

    		Others Others
    Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC50 value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells .
    Pedunculosumoside F
  • HY-N12105
    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside

    		HBV Infection
    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC50 values of 1.67 and >2.15 mM, respectively .
    Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside
  • HY-107454
    OSS_128167
    10+ Cited Publications

    		 Sirtuin HBV Infection Metabolic Disease Inflammation/Immunology Cancer
    OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC50s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects .
    OSS_128167
  • HY-B0150R
    Nicotinamide (Standard)
    Maximum Cited Publications
    36 Publications Verification

    Niacinamide(Standard); Nicotinic acid amide (Standard)

    		 Endogenous Metabolite Sirtuin Cancer
    Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide (Standard)
  • HY-W063968
    RO8191
    5+ Cited Publications

    CDM-3008; RO4948191

    		 IFNAR JAK STAT HCV HBV Infection
    RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .
    RO8191
  • HY-156665
    HBV-IN-37

    		HBV Infection
    HBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM .
    HBV-IN-37
  • HY-16680
    Helioxanthin 8-1

    Helioxanthin analogue 8-1

    		 HBV Infection
    Helioxanthin 8-1 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 uM.
    Helioxanthin 8-1
  • HY-N3861
    Erythrocentaurin

    		HBV Infection
    Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor .
    Erythrocentaurin
  • HY-N5086
    Picroside IV

    		HBV Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Picroside IV is an iridoid glycoside found in the underground parts of Picrorhiza scrophulariiflora. Picroside IV is a derivative of Catalpol (HY-N0820) . Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
    Picroside IV
  • HY-146394
    HBV-IN-22

    		HBV DNA/RNA Synthesis Infection
    HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively .
    HBV-IN-22
  • HY-147863
    HBV-IN-24

    		HBV Infection Neurological Disease
    HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC50 values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity .
    HBV-IN-24
  • HY-145060
    HBV-IN-13

    		HBV Infection
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor. From patent WO2021204252A1, compound 1_B .
    HBV-IN-13
  • HY-145053
    HBV-IN-10

    		HBV Infection
    HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
    HBV-IN-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: